Welcome to July’s research update from the AGITG.
Study Chairs: Prof John Zalcberg and A/Prof Sumitra Ananda
With GIST on the agenda this month, we are pleased to announce that SSGXXII has activated a site at Fiona Stanley Hospital, WA.
The success of this trial will be dependent upon referral of patients to participating sites. If you would like to check the eligibility of a potential candidate, please contact firstname.lastname@example.org.
About the SSGXXII trial
Help needed for SPAR recruitment
Study Chairs: A/Prof Michael Jameson and Prof Stephen Ackland
Funding for SPAR recruitment at Australian sites will finish in December.
There is still time to identify eligible patients for enrolment. If you wish to check the eligibility for a potential candidate, please email de-identified details to email@example.com.
RESOLUTE activates three new sites
Study Chairs: A/Prof Jeanne Tie and Dr Julie Chu
The RESOLUTE study continues to build momentum and has recently activated three new sites:
- St Vincent’s Hospital, VIC
- Border Medical Oncology Research Unit, NSW
- Bendigo Health, VIC
Congratulations to everyone involved.
RENO approaches 50% recruitment
Study Chairs: Prof Chris Karapetis and Dr Sina Vatandoust
Congratulations to Flinders Medical Centre for recruiting their 37th patient to the study. In total, the RENO study has enrolled 56 patients – nearly half of its target accrual.
In addition, congratulations to the Royal Darwin Hospital site for activating.
RoLaCaRT-1 reaches 50% recruitment, activates new site
Study Chair: Prof Andrew Stevenson
Congratulations to the RoLaCaRT-1 team for reaching 50% of its target patient recruitment. This makes a total of 17 patients recruited to the trial.
The trial has also just opened at Epworth HealthCare.
DYNAMIC-Pancreas reaches first milestone
Study Chairs: Dr Belinda Lee, A/Prof Jeanne Tie and Prof Peter Gibbs
Congratulations to the DYNAMIC-Pancreas team for reaching 25% of the target recruitment, a total of 111 patients.
Six sites in VIC, NSW and QLD are still to recruit patients – please refer eligible candidates to this trial.